Osimertinib is the first third-generation EGFR-TKI that was approved by the Food and Drug Administration (FDA) as a treatment for advanced NSCLC patients who harbor common EGFR mutations (Cross et al., 2014; Mok et al., 2017). Here, EGFR is linked to non-small cell lung carcinoma.